Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

  • Iida, Shinsuke; 
  • Ishikawa, Takayuki; 
  • Min, Chang Ki; 
  • Kim, Kihyun; 
  • Yeh, Su Peng; 
  • 외 10명
Citations

WEB OF SCIENCE

10
Citations

SCOPUS

8

초록

The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of Asian patients from COLUMBA. Eligible patients had >= 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or were double refractory. Co-primary endpoints were overall response rate (ORR) and maximum trough concentration (C-trough). Secondary endpoints included rates of infusion-related reactions, progression-free survival, and patient-reported satisfaction with therapy. Sixty-seven Asian patients (DARA SC, n = 30; DARA IV, n = 37) were randomized, including 42 Japanese patients (DARA SC, n = 18; DARA IV, n = 24). Comparable ORRs for DARA SC versus DARA IV were seen in the Asian cohort (66.7% vs 43.2%) and Japanese-only cohort (61.1% vs 54.2%), including patients weighing <= 65 kg. Similarity of C-trough was seen in both Asian and Japanese-only cohorts; the ratio of the geometric mean of the C-trough concentrations for DARA SC/DARA IV was 143.96% (90% confidence interval (CI), 112.03-185.00%) and 148.02% (90% CI, 113.32-193.34%), respectively. The Asian cohort (both treatment groups) and Japanese-only cohort (DARA SC group) experienced higher rates of grade 3/4 cytopenias compared with the global COLUMBA population, occurring predominantly in patients of low bodyweight; no patients discontinued treatment due to cytopenias. The Cancer Therapy Satisfaction Questionnaire results generally favored DARA SC. In the Asian and Japanese-only cohorts, DARA SC was comparable to DARA IV. The efficacy, pharmacokinetic, safety, and satisfaction results were generally consistent with the global COLUMBA population regardless of patient bodyweight. Identifier: NCT03277105

키워드

Daratumumab; Multiple myeloma; Asian; Japanese; Monoclonal antibody; Subcutaneous
제목
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
저자
Iida, Shinsuke; Ishikawa, Takayuki; Min, Chang Ki; Kim, Kihyun; Yeh, Su Peng; Usmani, Saad Z.; Mateos, Maria-Victoria; Nahi, Hareth; Heuck, Christoph; Qin, Xiang; Parasrampuria, Dolly A.; Gries, Katharine S.; Qi, Ming; Bahlis, Nizar; Ito, Shigeki
DOI
10.1007/s00277-021-04405-2
발행일
2021-04
유형
Article
저널명
Annals of Hematology
권
100
호
4
페이지
1065 ~ 1077